Nurix Therapeutics, Inc. (NRIX) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−7.3x

Market Cap

$2.71B

MomentumView details →

1D Return

+3.24%

YTD Return

+35.01%

RSI (14)

49.7

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−7.3x

Market Cap

$2.71B

RSI (14)

49.7

MomentumView details →

1D Return

+3.24%

YTD Return

+35.01%

SummaryUpdated May 1, 2026

Nurix Therapeutics, Inc. (NASDAQ:NRIX) is a biopharmaceutical company founded in 2009 and headquartered in San Francisco, California. The company went public in July 2020, raising capital to advance its innovative approach to drug discovery and development. Nurix focuses on developing small molecule therapies that leverage targeted protein degradation, a cutting-edge approach in biotechnology that aims to treat cancer and immune disorders by selectively destroying disease-causing proteins within cells.

Ask drillr about Nurix Therapeutics, Inc. →

ProfitabilityView details →

Gross Margin

−165.51%

Net Margin

−928.44%

EBITDA Margin

−869.64%

ROE (TTM)

−84.78%

ROA (TTM)

−63.74%

Asset Turnover

0.06x

GrowthView details →

Revenue YoY

−58.40%

EPS YoY

−32.18%

FCF YoY

−34.87%

Revenue CAGR 3Y

+29.55%

EPS CAGR 3Y

−5.90%

EBITDA YoY

−52.19%

EarningsView details →

EPS (Actual)

−$0.81

EPS Surprise

−10.96%

Beats (12Q)

5/12

Next Q EPS Est

−$0.13

Avg Surprise (4Q)

−8.79%

Rev Surprise

−40.85%

Capital & dividendView details →

Debt/Equity

0.14x

Current Ratio

6.34x

Quick Ratio

6.34x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

36.77M

Net Income (TTM)

−341.35M

Op. CF (TTM)

−293.70M

Next earningsOct 8, 2026 →

Latest newsMore news →

Nurix Therapeutics appointed Wes Burwell as its Chief Human Resources Officer on August 20, 2026.15d ago

Nurix Therapeutics' stock reached a new 52-week high of $26.04 on Tuesday after Royal Bank of Canada raised its price target.25d ago

Similar companies

Beijing Luzhu Biotechnology Co., Ltd.02480.HK BioDlink International Company Limited01875.HK Soleno Therapeutics, Inc.SLNO Clover Biopharmaceuticals, Ltd.02197.HK SELLAS Life Sciences Group, Inc.SLS Frontage Holdings Corporation01521.HK Find similar companies →

Latest newsMore news →

Nurix Therapeutics appointed Wes Burwell as its Chief Human Resources Officer on August 20, 2026.15d ago Nurix Therapeutics' stock reached a new 52-week high of $26.04 on Tuesday after Royal Bank of Canada raised its price target.25d ago